Sickle cell medications: how to pay less.
Hydroxyurea, voxelotor, crizanlizumab, L-glutamine — affordability paths.
Sickle cell medications range from hydroxyurea (~$30/month generic) to voxelotor and crizanlizumab (~$10,000+/month brand). Insurance approvals are inconsistent.
Why this matters for Black patients
Sickle cell disease is concentrated in Black and Latinx populations. Treatment access disparities are well-documented; payer denials are routine.
Strategies to pay less
Manufacturer copay assistance
Pfizer (Oxbryta), Novartis (Adakveo), and Emmaus (Endari) all run copay programs.
Sickle Cell Disease Association of America
SCDAA partner programs help with insurance denials and patient assistance applications.
340B-eligible institutions
Comprehensive sickle cell centers often access 340B pricing, which substantially lowers patient out-of-pocket costs.